Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication

Summary

This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.

Timeline

Start

2026-04-08

Primary completion

2030-12-31

Completion

2032-12-31

Drugs

Indications